相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mitochondria, energy, and metabolism in neuronal health and disease
Diogo Trigo et al.
FEBS LETTERS (2022)
Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)
Lina Titievsky et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
Chaperone therapy for molecular pathology in lysosomal diseases
Yoshiyuki Suzuki
BRAIN & DEVELOPMENT (2021)
Non-immune Hemolysis in Gaucher Disease and Review of the Literature
Eliyakim Hershkop et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2021)
Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment
Neal J. Weinreb et al.
MOLECULAR GENETICS AND METABOLISM (2021)
Successful Treatment of Gaucher Disease With Matched Sibling Hematopoietic Stem Cell Transplantation
Shevachut Chavananon et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2021)
Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
Margarita M. Ivanova et al.
PLOS ONE (2021)
Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1
Manasa P. Srikanth et al.
STEM CELLS TRANSLATIONAL MEDICINE (2021)
Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector
Maria Dahl et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Potential Treatment of Lysosomal Storage Disease through Modulation of the Mitochondrial-Lysosomal Axis
Myeong Uk Kuk et al.
CELLS (2021)
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Jan Styczynski et al.
BONE MARROW TRANSPLANTATION (2020)
Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes
Giulia Massaro et al.
HUMAN MOLECULAR GENETICS (2020)
Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease
Wenjun Jiang et al.
JOURNAL OF HUMAN GENETICS (2020)
CRISPR/Cas9 Editing for Gaucher Disease Modelling
Eleonora Pavan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3
Michael W. Wilson et al.
ACS CHEMICAL NEUROSCIENCE (2020)
Gene therapy: a double-edged sword with great powers
Ran Tang et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing
Samantha G. Scharenberg et al.
NATURE COMMUNICATIONS (2020)
Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome)
Weijing Kong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Allogeneic hematopoietic stem cell transplantation for treating severe lung involvement in Gaucher disease
Fu-Shiuan Lee et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2020)
Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naive patients with Gaucher disease
Ari Zimran et al.
BLOOD CELLS MOLECULES AND DISEASES (2019)
Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy as a Treatment Strategy in Mouse Models of Gaucher Disease
Sichen Du et al.
HUMAN GENE THERAPY (2019)
Entering the Modern Era of Gene Therapy
Xavier M. Anguela et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Marina Cavazzana et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
CRISPR-Cas9 system: A new-fangled dawn in gene editing
Darshana Gupta et al.
LIFE SCIENCES (2019)
Treatment-naive Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials
Ari Zimran et al.
BLOOD CELLS MOLECULES AND DISEASES (2018)
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project
Pilar Giraldo et al.
BLOOD CELLS MOLECULES AND DISEASES (2018)
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Pramod K. Mistry et al.
BLOOD CELLS MOLECULES AND DISEASES (2018)
How we manage Gaucher Disease in the era of choices
Shoshana Revel-Vilk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Fetal gene therapy for neurodegenerative disease of infants
Giulia Massaro et al.
NATURE MEDICINE (2018)
Gene Editing on Center Stage
Rasmus O. Bak et al.
TRENDS IN GENETICS (2018)
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Jerome Stirnemann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Generation of a homozygous GBA deletion human embryonic stem cell line
Anna Lisa Gundner et al.
STEM CELL RESEARCH (2017)
Protein misfolding in the endoplasmic reticulum as a conduit to human disease
Miao Wang et al.
NATURE (2016)
Mitochondrial fusion/fission dynamics in neurodegeneration and neuronal plasticity
A. M. Bertholet et al.
NEUROBIOLOGY OF DISEASE (2016)
Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients
Bouwien E. Smid et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
Aya Narita et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders
Maria Francisca Coutinho et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
In vivo genome editing of the albumin locus as a platform for protein replacement therapy
Rajiv Sharma et al.
BLOOD (2015)
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial
Timothy M. Cox et al.
LANCET (2015)
Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice
Maria Dahl et al.
MOLECULAR THERAPY (2015)
Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease
Mario de la Mata et al.
SCIENTIFIC REPORTS (2015)
Brief Reports: Lysosomal Cross-Correction by Hematopoietic Stem Cell-Derived Macrophages Via Tunneling Nanotubes
Swati Naphade et al.
STEM CELLS (2015)
TALEN-Mediated Generation and Genetic Correction of Disease-Specific Human Induced Pluripotent Stem Cells
Sivaprakash Ramalingam et al.
CURRENT GENE THERAPY (2014)
Long term differential consequences of miglustat therapy on intestinal disaccharidases
Mahdi Amiri et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2014)
Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study
David J. Kuter et al.
BLOOD CELLS MOLECULES AND DISEASES (2013)
Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease-Links to Parkinson's Disease
Laura D. Osellame et al.
CELL METABOLISM (2013)
A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models
Qiurong Ding et al.
CELL STEM CELL (2013)
Biosafety Features of Lentiviral Vectors
Axel Schambach et al.
HUMAN GENE THERAPY (2013)
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
Neal J. Weinreb et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2013)
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer
Marco Ranzani et al.
NATURE METHODS (2013)
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage
Michael W. J. Cleeter et al.
NEUROCHEMISTRY INTERNATIONAL (2013)
Gauchers Disease-A Reappraisal of Hematopoietic Stem Cell Transplantation
Sawa Ito et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2013)
The role of saposin C in Gaucher disease
Rafael J. Tamargo et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Retroviral Integrations in Gene Therapy Trials
Luca Biasco et al.
MOLECULAR THERAPY (2012)
Genome Engineering With Zinc-Finger Nucleases
Dana Carroll
GENETICS (2011)
Several rAAV Vectors Efficiently Cross the Blood-brain Barrier and Transduce Neurons and Astrocytes in the Neonatal Mouse Central Nervous System
Hongwei Zhang et al.
MOLECULAR THERAPY (2011)
Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures
Yannick Doyon et al.
NATURE METHODS (2011)
A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity
Claudio Mussolino et al.
NUCLEIC ACIDS RESEARCH (2011)
Gammaretroviral Vectors: Biology, Technology and Application
Tobias Maetzig et al.
VIRUSES-BASEL (2011)
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Gustavo H. B. Maegawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Miglustat (Zavesca®) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme
Carla E. M. Hollak et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Randomized, Controlled Trial of Miglustat in Gaucher's Disease Type 3
Raphael Schiffmann et al.
ANNALS OF NEUROLOGY (2008)
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III
J. Cox-Brinkman et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement
Deborah Elstein et al.
BLOOD (2007)
Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination
Jose L. Capablo et al.
EPILEPSIA (2007)
The long-term international safety experience of imiglucerase therapy for Gaucher disease
Kathryn Starzyk et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Effective cell and gene therapy in a murine model of Gaucher disease
Ida Berglin Enquist et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms
Richard A. Steet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients
Hui-Hwa Chang et al.
FEBS JOURNAL (2006)
AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease
Kerry Anne McEachern et al.
JOURNAL OF GENE MEDICINE (2006)
Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations
P Alfonso et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector
YB Hong et al.
JOURNAL OF HUMAN GENETICS (2004)
N-octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells:: a potential chemical chaperone therapy for Gaucher disease
H Lin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2004)
Enzyme replacement in Gaucher disease
E Beutler
PLOS MEDICINE (2004)
Therapeutic goals in the treatment of Gaucher disease
GM Pastores et al.
SEMINARS IN HEMATOLOGY (2004)
Gaucher disease and the clinical experience with substrate reduction therapy
A Zimran et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES (2003)
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry
NJ Weinreb et al.
AMERICAN JOURNAL OF MEDICINE (2002)
分享论文
